Welcome to our dedicated page for Biolinerx SEC filings (Ticker: BLRX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
BioLineRx Ltd. filings document the regulatory record of a foreign private issuer focused on oncology and rare-disease drug development. Recent Form 6-K reports include financial results, interim consolidated financial statements, operating and financial reviews, and press-release exhibits incorporated by reference into effective Securities Act registration statements.
The filings also record company-specific matters such as the GLIX1 collaboration and joint-venture agreements with Hemispherian, GLIX1 patent and clinical-development disclosures, motixafortide and APHEXDA commercial context, and a final arbitration award involving the motixafortide in-licensing agreement. These disclosures frame BioLineRx's business updates, capital commitments, intellectual-property position, legal contingencies, and governance authorization as a Nasdaq- and TASE-listed issuer.
BioLineRx reported first quarter 2026 results showing a net loss of $2.6M, compared with net income of $5.1M a year earlier, as research and development spending increased. Royalty revenue from partnerships rose to $0.5M, reflecting initial APHEXDA commercialization.
Cash, cash equivalents and short-term deposits totaled $17.4M as of March 31, 2026, with negative operating cash flow of $2.3M for the quarter. Management expects existing resources to fund operations into the first half of 2027, but explicitly notes material uncertainty that may cast significant doubt on the company’s ability to continue as a going concern.
Strategically, BioLineRx is pivoting to an R&D-focused model centered on oncology and rare diseases. The lead asset GLIX1 advanced with the first patient dosed in a Phase 1/2a glioblastoma trial, backed by encouraging preclinical data and Orphan Drug Designation in the US and EU. Motixafortide, already approved as APHEXDA for stem-cell mobilization, is now out-licensed globally, while the company retains development rights in solid tumors including metastatic pancreatic cancer supported by an ongoing Phase 2b trial.
BioLineRx Ltd. furnished a report highlighting new scientific data and clinical plans for GLIX1, its lead oncology program, in collaboration with Hemispherian AS. Two abstracts on GLIX1 will appear at the ASCO 2026 Annual Meeting, covering its novel TET2-targeting mechanism and synergy with PARP inhibitors across multiple cancers.
Preclinical studies show GLIX1 is an oral, brain-penetrant small molecule that restores TET2 activity, induces tumor-selective DNA damage, demonstrates antitumor activity in glioblastoma models, and was well tolerated in animal safety studies. A first-in-human Phase 1/2a trial in recurrent and progressive glioblastoma and other high-grade gliomas is enrolling, with Part 1 expected to include up to 30 patients and establish a recommended dose.
BioLineRx anticipates trial updates in the second half of 2026 and full dose-escalation results in 2027, with Phase 2a expansion cohorts planned in newly diagnosed glioblastoma and selected other cancers, including combinations with standard-of-care regimens and PARP inhibitors.
BioLineRx Ltd. files a Form 6-K highlighting new preclinical data for GLIX1 in glioblastoma (GBM). Together with Hemispherian, the company reports that orally administered GLIX1 showed robust anti-tumor activity in multiple in‑vivo GBM models, including a temozolomide (TMZ)-resistant patient-derived xenograft model where TMZ showed no effect.
The data support a Phase 1/2a open-label, multicenter trial of GLIX1 in recurrent and progressive GBM and other high‑grade gliomas, with dose escalation enrolling up to 30 patients to determine a maximum tolerated or recommended dose. Trial updates are anticipated during H2 2026, with full dose‑escalation results expected in 2027 and later Phase 2a expansion into newly diagnosed GBM and select other cancers.
BioLineRx Ltd. filed a Form 6-K highlighting a joint update with Hemispherian AS that the first patient has been dosed in a first-in-human, Phase 1/2a trial of GLIX1 for recurrent and progressive glioblastoma and other high-grade gliomas.
The study, conducted at leading U.S. cancer centers including NYU Langone Health, will initially enroll up to 30 patients in a Phase 1 dose-escalation stage to determine a maximum tolerated or recommended dose based on safety, pharmacokinetics/pharmacodynamics and preliminary efficacy. Initial Phase 1 data are anticipated in the first half of 2027.
GLIX1 is described as an oral, first-in-class small molecule designed to activate TET2 and selectively induce DNA damage in cancer cells, with strong preclinical activity and blood-brain-barrier penetration. A Phase 2a expansion is planned in newly diagnosed glioblastoma and selected other cancers, including combinations such as with PARP inhibitors.
BioLineRx Ltd. director Yan Shaoyu has filed an initial Form 3 insider report. The data shows no reported transactions, with buy, sell, acquire, and dispose counts all at zero. The filing also lists no derivative positions and no holding entries in this snapshot.
BioLineRx Ltd. director Sandra Panem filed an initial ownership report showing multiple employee stock options to buy Ordinary Shares. The options cover blocks such as 199,800 shares at an exercise price of $0.356 and 1,080,000 shares at $0.085, with expirations between 2026 and 2034.
Footnotes state that earlier grants from 2016 through 2024 are fully vested, while an October 1, 2024 grant left 856,200 options vested at appointment and 1,198,800 options scheduled to vest in seven equal quarterly installments, subject to her continued service.
BioLineRx Ltd. director Raphael Hofstein filed an initial ownership report showing he holds several employee stock options over the company’s ordinary shares. This Form 3 does not report new purchases or sales, but lists option grants previously awarded under the company’s 2003 Amended and Restated Share Incentive Plan.
The disclosed positions include options exercisable at prices such as $0.8370, $0.9200, and as low as $0.0520 per share, with expiration dates ranging from July 2026 to August 2034. Footnotes state that most grants are already fully vested, while a large grant covering 2,055,000 underlying shares at $0.0520 has 856,200 options vested and 1,198,800 scheduled to vest in seven equal quarterly installments, contingent on his continued service.
BioLineRx Ltd. director Dar Rami reported initial holdings of employee stock options over Ordinary Shares. The Form 3 shows several option grants with exercise prices between $0.052 and $0.085, expiring between 2032 and 2034, granted under the 2003 Amended and Restated Share Incentive Plan.
One grant over 2,055,000 underlying shares at an exercise price of $0.052 includes 856,200 options vested as of the appointment date, with the remaining 1,198,800 vesting in seven equal quarterly installments, subject to continued service.
BioLineRx Ltd. director Molcho Avraham filed an initial ownership report showing a portfolio of employee stock options to acquire Ordinary Shares. The filing lists multiple fully vested grants made between July 2016 and July 2024 under the 2003 Amended and Restated Share Incentive Plan, with exercise prices ranging from $0.052 to $0.920 per share and expirations between 2026 and 2034. One large grant covers 2,055,000 underlying shares at an exercise price of $0.052 per share, expiring in 2034, of which 856,200 options were vested on the October 1, 2024 grant date and the remaining 1,198,800 options vest in seven equal quarterly installments, subject to continued service.
BioLineRx Ltd. director Cohen Gal Avraham filed an initial ownership report detailing employee stock options over 2,055,000 underlying ordinary shares. These options carry an exercise price of $0.052 per share and expire on August 14, 2034.
The options were granted on October 1, 2024 under the company’s 2003 Amended and Restated Share Incentive Plan. As of the grant date, 856,200 options were vested, with the remaining 1,198,800 scheduled to vest in seven equal quarterly installments, subject to continued service. The filing reflects holdings only and does not report any purchases or sales.